Physician profile
Dory B Altmann
NPI 1114954005
$5,234.07
in general payments reported to CMS, 2019-2025
34 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $469 · 2021: $975 · 2022: $898 · 2023: $570 · 2024: $766 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,016.01 | 2019-2025 | |
| Amgen INC. | $604.13 | 2019-2025 | Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $537.55 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $414.76 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $300.09 | 2021-2025 | Verquvo |
| Pfizer INC. | $232.65 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $228.61 | 2022-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $227.66 | 2022-2025 | Onpattro |
| Boston Scientific Corporation | $202.20 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.91 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $153.49 | 2019-2021 | |
| Abbott Laboratories | $148.42 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $114.96 | 2019-2025 | Impella |
| Novo Nordisk INC | $106.64 | 2024-2025 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.23 | 2020-2024 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $72.16 | 2025 | Attruby |
| Daiichi Sankyo INC. | $66.74 | 2022-2023 | Injectafer |
| Heartflow, INC. | $61.86 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $59.93 | 2019-2024 | Evkeeza |
| Arbor Pharmaceuticals, INC. | $46.99 | 2020-2021 | |
| Esperion Therapeutics, INC. | $46.43 | 2022-2024 | Nexletol |
| Atricure, INC. | $44.31 | 2024-2025 | Atriclip Laa Exclusion System |
| Astrazeneca Pharmaceuticals LP | $44.15 | 2020-2025 | Lokelma |
| Gilead Sciences, INC. | $40.03 | 2019 | |
| W. L. Gore & Associates, INC. | $33.79 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.67 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $28.90 | 2022 | |
| Lilly USA, LLC | $18.97 | 2025 | Zepbound |
| Tactile Systems Technology INC | $16.11 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.46 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $14.78 | 2024 | Arcalyst |
| Jazz Pharmaceuticals INC. | $14.46 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2025 | |
| Medtronic Vascular, INC. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dory Altmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.